LogicBio Therapeutics, Inc. (LOGC): Price and Financial Metrics
LogicBio Therapeutics, Inc. (LOGC)
Today's Latest Price: $8.26 USD
Updated Jan 27 6:55pm
Add LOGC to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 64 in Medical - Diagnostics/Research
See all "A" rated Strong Buy stocks
LOGC Stock Summary
- LogicBio Therapeutics Inc's stock had its IPO on October 19, 2018, making it an older stock than just 5.03% of US equities in our set.
- With a price/sales ratio of 90.16, LogicBio Therapeutics Inc has a higher such ratio than 96.19% of stocks in our set.
- Revenue growth over the past 12 months for LogicBio Therapeutics Inc comes in at 185.21%, a number that bests 96.64% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to LogicBio Therapeutics Inc are VIE, LPTX, XFOR, CRIS, and BCRX.
- Visit LOGC's SEC page to see the company's official filings. To visit the company's web site, go to www.logicbio.com.
LOGC Stock Price Chart Interactive Chart >
LOGC Price/Volume Stats
| Current price | $8.26 | 52-week high | $11.60 |
| Prev. close | $8.71 | 52-week low | $3.05 |
| Day low | $7.94 | Volume | 189,100 |
| Day high | $8.73 | Avg. volume | 124,218 |
| 50-day MA | $7.67 | Dividend yield | N/A |
| 200-day MA | $7.17 | Market Cap | 262.55M |
LogicBio Therapeutics, Inc. (LOGC) Company Bio
LogicBio Therapeutics, Inc. is a genome editing company, which engages in developing medicines to treat rare diseases in patients with significant unmet medical need. It focuses on the commercialization of specific genome editing and integration of the therapeutic transgene. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Cambridge, MA.
Loading social stream, please wait...